🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Melanoma

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663Phase 1, Phase 23 sites📍 Beijing📍 Zhengzhou📍 Hangzhou Beijing Tide Pharmaceutical Co., Ltd · Tests: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg, benmelstobart Injection Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma NCT06008106Phase 31 site📍 Beijing Shanghai Kechow Pharma, Inc. · Tests: tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Naltrexone and Propranolol Combined With Immunotherapy NCT05968690Phase 11 site📍 New Brunswick Sarah Weiss · Tests: Propranolol, Naltrexone A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors NCT05366478Phase 11 site📍 Tianjin Suzhou BlueHorse Therapeutics Co., Ltd. · Tests: Autologous tumor infiltrating lymphocytes (TILs) Study of GV20-0251 in Participants With Solid Tumor Malignancies NCT07070518Phase 1, Phase 23 sites📍 Beijing📍 Beijing📍 Shanghai GV20 Therapeutics · Tests: GV20-0251 A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites📍 Clovis📍 Los Angeles📍 Newport Beach Bristol-Myers Squibb · Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC NCT07718243Phase 1, Phase 22 sites📍 Manchester📍 Sutton Institute of Cancer Research, United Kingdom · Tests: Bexmarilimab 1mg/kg and nivolumab 1mg/kg, Bexmarilimab 3mg/kg and nivolumab 1mg/kg, Recommended Phase II Dose Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) NCT05549297Phase 382 sites📍 Phoenix📍 Jacksonville📍 Orlando Immunocore Ltd · Tests: Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice Mirdametinib in Patients With Advanced NF1-mutant Melanoma NCT07237100Phase 21 site📍 San Francisco Kevin Kim, MD · Tests: Mirdametinib An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors NCT06942143Phase 11 site📍 Guangzhou Guangzhou FineImmune Biotechnology Co., LTD. · Tests: Super1 TCR-T Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma NCT04598009Phase 22 sites📍 La Jolla📍 San Francisco University of California, San Francisco · Tests: Binimetinib, Imatinib A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites📍 Grand Rapids📍 St Louis📍 Pittsburgh AstraZeneca · Tests: AZD6750, rilvegostomig Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial NCT07155317Phase 22 sites📍 Atlanta📍 Atlanta Emory University · Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging VSV-02 Compassionate Use in Advanced Solid Tumors NCT07260591Phase 11 site📍 Xinxiang The First Affiliated Hospital of Xinxiang Medical College · Tests: VSV-02 Injection Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis NCT06899789n/a1 site📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites📍 Duarte📍 Los Angeles📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-1607, Paclitaxel A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer NCT06636435Phase 15 sites📍 Kashiwa📍 Yokohama📍 Niigata Chiome Bioscience Inc. · Tests: CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3, CBA-1205 Part 4, CBA-1205 Part 5 EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EBNK-001 + IL-15 + Pembrolizumab A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors NCT05970497Phase 1, Phase 215 sites📍 Los Angeles📍 Rancho Santa Margarita📍 Weston Krystal Biotech, Inc. · Tests: KB707, Opdualag, KEYTRUDA ®( Pembrolizumab) A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies NCT05669430Phase 1, Phase 213 sites📍 Los Angeles📍 Denver📍 New Haven GV20 Therapeutics · Tests: GV20-0251, GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], GV20-0251 and Pembrolizumab [KEYTRUDA®] Symptom Management and Survivorship Plus Coaching for Advanced Cancer Survivors and Their Caregivers NCT07415564NA1 site📍 Tucson University of Arizona · Tests: Symptom Management and Survivorship Handbook + Coaching, Symptom Management and Survivorship Handbook A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors NCT07070232Phase 1, Phase 277 sites📍 Phoenix📍 San Francisco📍 Hartford BioNTech SE · Tests: BNT326, Pumitamig, Itraconazole, Paroxetine Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma NCT06295159Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Nivolumab, Nivolumab + Relatlimab, Ipilimumab GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors NCT06265025Phase 1, Phase 24 sites📍 Goyang-si📍 Seoul📍 Seoul GeneMedicine Co., Ltd. · Tests: GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C) Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo) NCT05663775Phase 21 site📍 Edmonton AHS Cancer Control Alberta · Tests: Mesalamine A Study of DXC014 in Patients With Advanced Solid Tumors. NCT07177937Phase 15 sites📍 Beijing📍 Changsha📍 Nanchang Hangzhou DAC Biotechnology Co., Ltd. · Tests: DXC014 Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma NCT05983237Phase 1, Phase 21 site📍 Beijing Jun Guo · Tests: Fluzoparib Camrelizumab Temozolomide Neoadjuvant Tebentafusp for Uveal Melanoma NCT06414590Phase 22 sites📍 Philadelphia📍 Philadelphia Thomas Jefferson University · Tests: Tebentafusp-Tebn A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors NCT07600476Phase 13 sites📍 Munich📍 Würzburg📍 Münster Kupando GmbH · Tests: KUP-101A
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy